<DOC>
	<DOCNO>NCT02325050</DOCNO>
	<brief_summary>The purpose study test safety immunogenicity MVA-BN-Filo Ad26.ZEBOV heterologous homologous prime-boost vaccine regimens healthy adult participant .</brief_summary>
	<brief_title>A Safety Immunogenicity Study Heterologous Homologous Prime-Boost Ebola Vaccine Regimens Healthy Participants</brief_title>
	<detailed_description>This study consist 3 part : first third part standard dose second part high dos . All part randomize , placebo-controlled , observer-blind evaluate safety , tolerability immunogenicity MVA-BN-Filo Ad26.ZEBOV administer different dos , sequence schedule healthy adult participant . The study consist screen period 28 day , vaccination period participant vaccinate baseline ( Day 1 ) follow boost Day 15 , 29 , 57 , third vaccine 1-year post-prime ( 3rd vaccination optional subject group 1-8 ) . The total duration study 1 year participant wiil receive boost vaccine 3 month participant receive placebo 2 year participant receive 3rd dose . Safety monitor study .</detailed_description>
	<criteria>Must healthy basis physical examination , medical history , investigator 's clinical judgment Have body mass index ( BMI ) ≥18.5 &lt; 35.0 kg/m2 Women childbearing potential must negative serum βhuman chorionic gonadotropin pregnancy test screening , negative urine pregnancy test immediately prior study vaccine administration , practice adequate birth control measure 28 day prime vaccination least 3 month boost vaccination specify study protocol . If heterosexually active screening , must agree practice adequate birth control measure become heterosexually active participation study ( screen onwards least 3 month boost vaccination ) . Agree donate egg ( ovum , oocytes ) purpose assist reproduction participation study ( screen onwards least 3 month boost vaccination ) Women nonchildbearing potential , define postmenopausal ( &gt; 45 year age amenorrhea ≥2 year age amenorrhea ≥6 month serum folliclestimulating hormone [ FSH ] &gt; 40 mIU/mL ) surgically sterile ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) , require use birth control method specify study protocol A man vasectomy sexually active woman childbearing potential must agree use doublebarrier method birth control , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . In case female partner use adequate method birth control , singlebarrier method birth control male subject acceptable . Men must also agree donate sperm participation study ( screen onwards least 3 month boost vaccination ) Must available willing participate duration study visit followup , provide verifiable identification , mean contact Has vaccinate candidate Ebola vaccine Has diagnose Ebola disease expose Ebola include travel West Africa last 12 month . West Africa include limited country Guinea , Liberia , Mali , Sierra Leone . Participants anticipate travel epidemic Ebola area start longterm followup period also exclude enrollment study Has receive Ad26 MVAbased candidate vaccine past Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product ( include constituent study vaccine ) , include know allergy egg aminoglycosides A woman pregnant breastfeeding , plan become pregnant enrolled study within 3 month boost vaccination History diabetes mellitus type 1 type 2 , include case control diet alone ; thyroidectomy , thyroid disease require medication last 12 month ; uncontrolled hypertension define study protocol ; , major psychiatric illness and/or substance abuse problem past 12 month opinion investigator would preclude participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola Viral Disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>monovalent vaccine</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara - Bavarian Nordic ( MVA-BN ) Filo-vector</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>